237 related articles for article (PubMed ID: 19435929)
1. The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity.
Sirohi S; Dighe SV; Madia PA; Yoburn BC
J Pharmacol Exp Ther; 2009 Aug; 330(2):513-9. PubMed ID: 19435929
[TBL] [Abstract][Full Text] [Related]
2. Mu-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy.
Sirohi S; Kumar P; Yoburn BC
J Pharmacol Exp Ther; 2007 Nov; 323(2):701-7. PubMed ID: 17698975
[TBL] [Abstract][Full Text] [Related]
3. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
Raehal KM; Lowery JJ; Bhamidipati CM; Paolino RM; Blair JR; Wang D; Sadée W; Bilsky EJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):1150-62. PubMed ID: 15716384
[TBL] [Abstract][Full Text] [Related]
4. The role of opioid antagonist efficacy and constitutive opioid receptor activity in the opioid withdrawal syndrome in mice.
Navani DM; Sirohi S; Madia PA; Yoburn BC
Pharmacol Biochem Behav; 2011 Oct; 99(4):671-5. PubMed ID: 21736895
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-naïve and morphine-dependent mice.
Divin MF; Holden Ko MC; Traynor JR
Eur J Pharmacol; 2008 Mar; 583(1):48-55. PubMed ID: 18275956
[TBL] [Abstract][Full Text] [Related]
6. In vivo characterization of the opioid antagonist nalmefene in mice.
Osborn MD; Lowery JJ; Skorput AG; Giuvelis D; Bilsky EJ
Life Sci; 2010 Apr; 86(15-16):624-30. PubMed ID: 20159022
[TBL] [Abstract][Full Text] [Related]
7. Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management.
Sadee W; Oberdick J; Wang Z
Molecules; 2020 Sep; 25(18):. PubMed ID: 32932935
[TBL] [Abstract][Full Text] [Related]
8. 6beta-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice.
Yancey-Wrona JE; Raymond TJ; Mercer HK; Sadée W; Bilsky EJ
Life Sci; 2009 Sep; 85(11-12):413-20. PubMed ID: 19583969
[TBL] [Abstract][Full Text] [Related]
9. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.
Wang D; Raehal KM; Bilsky EJ; Sadée W
J Neurochem; 2001 Jun; 77(6):1590-600. PubMed ID: 11413242
[TBL] [Abstract][Full Text] [Related]
10. Differential in vivo potencies of naltrexone and 6beta-naltrexol in the monkey.
Ko MC; Divin MF; Lee H; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2006 Feb; 316(2):772-9. PubMed ID: 16258020
[TBL] [Abstract][Full Text] [Related]
11. Comparison of naltrexone, 6alpha-naltrexol, and 6beta-naltrexol in morphine-dependent and in nondependent rhesus monkeys.
Li JX; McMahon LR; France CP
Psychopharmacology (Berl); 2008 Jan; 195(4):479-86. PubMed ID: 17874317
[TBL] [Abstract][Full Text] [Related]
12. Ligand-Free Signaling of G-Protein-Coupled Receptors: Relevance to μ Opioid Receptors in Analgesia and Addiction.
Sadee W; McKew JC
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144565
[TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone.
Porter SJ; Somogyi AA; White JM
Addict Biol; 2002 Apr; 7(2):219-25. PubMed ID: 12006217
[TBL] [Abstract][Full Text] [Related]
14. Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.
Divin MF; Bradbury FA; Carroll FI; Traynor JR
Br J Pharmacol; 2009 Apr; 156(7):1044-53. PubMed ID: 19220294
[TBL] [Abstract][Full Text] [Related]
15. Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence.
Walker EA; Sterious SN
Br J Pharmacol; 2005 Aug; 145(7):975-83. PubMed ID: 15912139
[TBL] [Abstract][Full Text] [Related]
16. 6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study.
Yancey-Wrona J; Dallaire B; Bilsky E; Bath B; Burkart J; Webster L; Magiera D; Yang X; Phelps M; Sadee W
Pain Med; 2011 Dec; 12(12):1727-37. PubMed ID: 22123184
[TBL] [Abstract][Full Text] [Related]
17. Methocinnamox Produces Long-Lasting Antagonism of the Behavioral Effects of
Gerak LR; Minervini V; Latham E; Ghodrati S; Lillis KV; Wooden J; Disney A; Husbands SM; France CP
J Pharmacol Exp Ther; 2019 Nov; 371(2):507-516. PubMed ID: 31439807
[TBL] [Abstract][Full Text] [Related]
18. Endothelin ETA receptor antagonist reverses naloxone-precipitated opioid withdrawal in mice.
Bhalla S; Pais G; Tapia M; Gulati A
Can J Physiol Pharmacol; 2015 Nov; 93(11):935-44. PubMed ID: 26440527
[TBL] [Abstract][Full Text] [Related]
19. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment.
Crain SM; Shen KF
Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10540-4. PubMed ID: 7479836
[TBL] [Abstract][Full Text] [Related]
20. Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
Crain SM; Shen KF
Brain Res; 2007 Sep; 1167():31-41. PubMed ID: 17692296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
